Evidence map›Paper›PMID 41657311›Full record

ArticleJCI insight2026

Tracing the molecular route to progression in miRNA-biogenesis-defective thyroid lesions.

Anne-Sophie Chong, Carla Roca, Paula Morales-Sánchez, Eduard Dorca, Verónica Barea, Ignacio Ruz-Caracuel, Pablo Valderrabano, Carlota Rovira, Cristina Jou, Dorothée Bouron-Dal Soglio and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Anne-Sophie ChongProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Carla RocaProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Paula Morales-SánchezDepartment of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
Eduard DorcaPathology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.
Verónica BareaGenetics and Genomics, Faculty of Biology, University of Barcelona, Barcelona, Spain.
Ignacio Ruz-CaracuelRamón y Cajal Health Research Institute (IRYCIS), Ramón y Cajal University Hospital, CIBERONC, Madrid, Spain.
Pablo ValderrabanoDepartment of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
Carlota RoviraDepartment of Pathology, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
Cristina JouDepartment of Pathology, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
Dorothée Bouron-Dal SoglioCentre Hospitalier Universitaire Sainte-Justine Research Center, Université de Montréal, Montréal, Quebec, Canada.
Rebecca D ChernockDepartment of Pathology and Immunology, and.
Giovana T TorrezanClinical and Functional Genomics Group, International Research Center/CIPE, A.C. Camargo Cancer Center, São Paulo, Brazil.
Marc PusztaszeriDepartment of Pathology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
José M Cameselle-TeijeiroDepartment of Pathology, Clinical University Hospital of Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela, Santiago de Compostela, Spain.
Xavier Matias-GuiuDepartment of Pathology, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA, Lleida, Spain.
Clara V AlvarezNeoplasia & Endocrine Differentiation P0L5, Centre for Research in Molecular Medicine and Chronic Disease (CIMUS), Santiago de Compostela, Spain.
Héctor SalvadorDepartment of Oncology, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
Jonathan D WassermanDivision of Endocrinology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Luis Javier Leandro-GarcíaHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
William D FoulkesDepartment of Human Genetics, and.
Eduardo Andrés-LeónBioinformatics Unit, Institute of Parasitology and Biomedicine López-Neyra (IPBLN), CSIC, Granada, Spain.
Paula Casano-SanchoPediatric Endocrinology Department, Institut de Recerca Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
Barbara RiveraProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Germline and somatic changes in DICER1 and DGCR8 microprocessors confer risk of developing benign and malignant thyroid lesions, yet the molecular events driving malignant transformation remain unclear. We trace the molecular trajectories from benignity to malignancy in DICER1- and DGCR8-mutated thyroid lesions using multiomic profiling on over 30 DICER1-/DGCR8-mutated samples. Our findings reveal a progressive, specific, and linear accumulation of genetic changes, which when combined with enhanced downregulation of miRNAs distinguished DICER1-/DGCR8-malignant lesions from their benign counterparts. Compensatory hypomethylation of miRNA-encoding genes characterized DICER1-/DGCR8-benign lesions, but as the tumors progressed to malignancy, methylation was partly reimposed, reversing the attempts to activate miRNA-encoded genes and further compromising miRNA production. Transcriptomic analyses revealed mutation-specific effects on the microenvironment, whereby DICER1 mutations activated canonical thyroid cancer progression pathways, whereas altered DGCR8 associated with immune-related changes. This work unveils specific molecular events underlying malignant progression of miRNA-biogenesis-related thyroid tumors and identifies potential biomarkers and disease etiology mechanisms.

Indexed as

DEAD-box RNA HelicasesMicroRNAsRibonuclease IIIRNA-Binding ProteinsThyroid NeoplasmsDisease ProgressionGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMutationThyroid GlandDEAD-box RNA HelicasesDGCR8 protein, humanDICER1 protein, humanMicroRNAsRibonuclease IIIRNA-Binding ProteinsEndocrinologyGeneticsOncologyRNA processingThyroid diseaseTranscriptomics

Identifiers

PMID41657311
PMCPMC12893109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.